Author(s): Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T,
Abstract Share this page
Abstract OBJECTIVE: Response to pegylated (PEG) interferon (IFN) and ribavirin is achieved only in 40-50\% of patients infected with hepatitis C virus (HCV) of genotype 1 in high viral loads, which needs to be improved. METHODS: In an open-label pilot study, fluvastatin (HMG-CoA reductase inhibitor), 20 mg daily, was given along with PEG-IFN/ribavirin to 21 patients with chronic hepatitis C. They were followed for HCV RNA in serum. RESULTS: During treatment for 48 weeks, HCV RNA was lost from serum in 93\% of the patients. In the 15 patients who received 48-week therapy, a sustained virological response (SVR) with loss of HCV RNA 24 weeks after completion was achieved in 10 (67\%), including 7 of the 9 (78\%) male and 3 of the 6 (50\%) female patients. In the remaining 6 patients who received 72-week therapy, SVR was gained in 4 (67\%), including 1 of the 2 male and 3 of the 4 female patients aged 56, 58 and 62 years, respectively. CONCLUSION: Fluvastatin could be used safely to increase the response to PEG-IFN and ribavirin, especially in aged women who respond poorly to combined PEG-IFN/ribavirin. Copyright 2009 S. Karger AG, Basel.
This article was published in Intervirology
and referenced in Journal of Hepatology and Gastrointestinal disorders